Showing 15 posts of 16 posts found.

Daiichi Sankyo

NICE recommends Daiichi’s Lixiana for blood clots

July 13, 2015
Sales and Marketing DVT, Daiichi, Daiichi Sankyo, Lixiana, NICE, NOACs, VTE, anticoagulant, blood clots, edoxaban, novel anticoagulant. PE

Daiichi Sankyo has won a speedy approval from NICE, after the NHS guidance body approved its newly-launched blood clotting drug …

Daiichi image

Daiichi Sankyo launches clotting drug Lixiana in UK

July 10, 2015
Medical Communications, Sales and Marketing Daiichi Sankyo, Lixiana, NOAC, VTE, anticoagulant, atrial fibrillation, blood clots, edoxaban, novel anticoagulant, strokes, warfarin

Daiichi Sankyo’s Lixiana has become the latest pharma offering in the class of newer oral anticoagulants in the UK.Lixiana (edoxaban) …

Pradaxa image

Boehringer gets NICE nod for Pradaxa

December 16, 2014
Sales and Marketing Boehringer, NHS, NICE, Pradaxa, VTE, dagibatran, ingelheim, warfarin

NICE has confirmed a recommendation for Boehringer Ingelheim’s controversial anti-blood clotting drug Pradaxa, as a treatment for blood clots in …

Daiichi Sankyo image

Edoxaban ‘as effective as warfarin’

September 2, 2013
Sales and Marketing DVT, Daiichi Sankyo, VTE, warfarin

Daiichi Sankyo is celebrating after its once-a-day blood thinner edoxaban proved as effective as warfarin in a late-stage trial, although …

EMA offices, London

EMA starts contraceptive safety review

January 30, 2013
Manufacturing and Production, Sales and Marketing EMA, PRAC, VTE, contraception

Europe’s health regulator is to examine the safety of newer forms of contraceptive pills following concerns over potential health risks …

Xarelto image

NICE yes for Xarelto to treat blood clots

July 25, 2012
Sales and Marketing Bayer, DVT, NHS, NICE, Pradaxa, VTE, Xarelto

NICE is recommending Bayer’s Xarelto (rivaroxaban) for the treatment and prevention of deep vein thrombosis (DVT). The watchdog said in …

Eliquis launched in the UK

September 19, 2011
Sales and Marketing Eliquis, Pradaxa, VTE, Xarelto

Eliquis, the latest entrant to the competitive oral anticoagulant market, has been launched in the UK.Co-developed and co-marketed by Pfizer …

Sanofi's VTE avatar

Digital Pharma: online campaign directory updated

March 4, 2011
Medical Communications, Sales and Marketing Digital Pharma blog, Novartis, Pfizer, Sanofi-Aventis, VTE, diabetes, erectile dysfunction, pharmacist educaiton, venous thromboembolism, viagra

The latest update to the Digital Pharma links directory covers its online campaigns section and includes a pharmacist networking portal …

Blog footer

Digital Pharma: NHS thrombosis e-learning

January 14, 2011
Medical Communications Bayer, Boehringer Ingelheim, Digital Pharma blog, NHS training, Pfizer, Sanofi-Aventis, VTE, e-learning, venous thromboembolism

The NHS has launched a best-practice website to help educate healthcare professionals about one of the most common causes of …

VTE trial boost for Pfizer and BMS’ apixaban

December 31, 2010
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Pfizer, VTE, apixaban, enoxaparin, venous thromboembolism

Pfizer and Bristol-Myers Squibb’s oral anticoagulant apixaban has shown benefits over a standard injectable treatment for venous thromboembolism in a …

New anti-clotting drugs: stopping the silent killers

June 28, 2010
Research and Development, Sales and Marketing Pradaxa, VTE, Xarelto, atrial fibrilation, thrombosis

Blood clots are a major killer, but the threat they pose is poorly understood by the general public compared to …

Blood clot

Encouraging data for ThromboGenics and BioInvent product

May 7, 2010
BioInvent, Lovenox, ThromboGenics, VTE

An antibody-based drug to prevent blood clots after orthopaedic surgery has shown promising results in phase II. TB-402 is a …

Patients ignorant of blood clot risks

April 14, 2010
Sales and Marketing Pradaxa, VTE, thrombosis

Many patients are not aware that they are at risk from blood clots when staying in hospital, according to new …

Study boost for atrial fibrillation drugs

March 17, 2010
Research and Development Pradaxa, VTE, Xarelto, apixaban, betrixaban

Two rival drugs have both shown benefits over warfarin in patients with atrial fibrillation, according to new research. Boehringer Ingelheim’s …

Blood clot

Phase III success for apixaban

March 5, 2010
Research and Development BMS, Pfizer, VTE, apixaban

Pfizer and Bristol-Myers Squibb’s apixaban has shown promising results in a late-stage head-to-head trial with Sanofi-Aventis’ Lovenox. The oral anti-coagulant …

Latest content